Leerink analyst Jonathan Chang raised the firm’s price target on Replimune (REPL) to $21 from $18 to reflect an increased probability of ...

"The £1.4M raised by LFFM London will have a transformative impact on our mission," said Stephanie Kauffman, president of the Melanoma Research Alliance. "This generous support allows us to ...

H.C. Wainwright analyst Raghuram Selvaraju increased the price target on Replimune Group (NASDAQ:REPL), currently trading at $13.79 with a market cap of $1.06 billion, to $22.00, up from the previous ...

The leveraged finance and private equity communities came together on 29 January 2025 for the inaugural Leveraged Finance Fights Melanoma (LFFM) London benefit ...